Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA internal medicine"
DOI: 10.1001/jamainternmed.2023.1245
Abstract: Importance Clinical guidelines on chronic obstructive pulmonary disease (COPD) recommend inhalers containing long-acting muscarinic antagonists (LAMAs) and long-acting β-agonists (LABAs) over inhalers containing inhaled corticosteroids (ICSs) and LABAs. However, data from randomized clinical trials comparing… read more here.
Keywords: laba therapy; ics laba; chronic obstructive; lama laba ... See more keywords
Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β2-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary Care
Sign Up to like & getrecommendations! Published in 2019 at "Drugs"
DOI: 10.1007/s40265-019-01224-8
Abstract: The inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) fluticasone propionate/formoterol fumarate (FP/FORM; Flutiform®) has been available as fixed-dose combination (FDC) therapy for asthma patients aged ≥ 12 years in the UK since 2012. This post-authorisation safety study examined adverse… read more here.
Keywords: formoterol; fdc ics; study; form ... See more keywords
[New approaches of inhaled steroid asthma management in mild to moderate asthma].
Sign Up to like & getrecommendations! Published in 2019 at "Presse medicale"
DOI: 10.1016/j.lpm.2019.03.006
Abstract: Inhaled corticosteroids (ICS) are the cornerstone of the management of asthma. Daily use allows to reduce mortality, intensity and frequency of exacerbations, to increase the control of symptoms of asthma and the quality of life… read more here.
Keywords: combination; control symptoms; dose ics; management ... See more keywords
Prevalence and management of COPD and heart failure comorbidity in the general practitioner setting.
Sign Up to like & getrecommendations! Published in 2017 at "Respiratory medicine"
DOI: 10.1016/j.rmed.2017.07.059
Abstract: BACKGROUND COPD frequently coexists with HF with which shares several risk factors. A greater collaboration is required between cardiologists and pulmonologists to better identify and manage concurrent HF and COPD. This observational, retrospective study provides… read more here.
Keywords: copd patients; treatment; prevalence; management ... See more keywords
One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings.
Sign Up to like & getrecommendations! Published in 2019 at "Respiratory medicine"
DOI: 10.1016/j.rmed.2019.105859
Abstract: INTRODUCTION Global Initiative for Asthma (GINA) recommends medium- or high-dose inhaled corticosteroid-long-acting β2-agonist (ICS-LABA) as preferred treatments for patients with moderate-to-severe asthma. Limited data is available on how step 4/5 patients respond to ICS-LABA and… read more here.
Keywords: high dose; treatment; medium high; ics laba ... See more keywords
COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort.
Sign Up to like & getrecommendations! Published in 2021 at "Respiratory medicine"
DOI: 10.1016/j.rmed.2021.106461
Abstract: BACKGROUND Lung function impairment in COPD is known to be related to reductions of left heart size, while short-term interventional trials with bronchodilators showed positive effects on cardiac parameters. We investigated whether COPD maintenance therapy… read more here.
Keywords: laba lama; copd maintenance; ics laba; medication ... See more keywords
Significant percentage of asthma patients failed to achieve control in the first year after initiating medium or high dose ICS/LABA
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.pa3866
Abstract: Background: Current guidelines recommend the use of ICS/LABA to control moderate to severe asthma. Poor response to ICS/LABA is still observed in a sizeable proportion of patients. Objectives: Among asthma patients who newly initiated medium… read more here.
Keywords: asthma patients; control; treatment; year ... See more keywords
User-life of ICS/LABA inhaler devices should be considered when prescribed as relievers
Sign Up to like & getrecommendations! Published in 2021 at "European Respiratory Journal"
DOI: 10.1183/13993003.03921-2020
Abstract: Inhaled corticosteroid/formoterol (ICS/FOR) combination medications were initially developed as maintenance therapy; more recently they are also used as relievers in Europe and this use is proposed in the USA. ICS coupled with FOR (a long-acting… read more here.
Keywords: user life; inhaler; inhaler devices; ics laba ... See more keywords
Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.congress-2018.pa4385
Abstract: Rationale: Current GOLD strategy document positions both combination regimens of inhaled corticosteroid plus a long-acting β2-agonist [i.e. ICS/LABA] and long-acting muscarinic antagonist plus LABA [i.e. LAMA/LABA] for symptomatic patients with recurrent exacerbations. Methods: The InforMing… read more here.
Keywords: treatment; ics laba; lung function; lama laba ... See more keywords
Real-life effectiveness of indacaterol/glycopyrronium/mometasone for symptomatic relief of cough after switching from inhaled corticosteroid/long-acting β2-agonist therapy in patients with asthma: REACH study design
Sign Up to like & getrecommendations! Published in 2022 at "ERJ Open Research"
DOI: 10.1183/23120541.00452-2022
Abstract: Cough is a major symptom in patients with asthma and poses a significant burden compared with other asthma symptoms. However, there are no approved treatments in Japan, developed to specifically treat cough in patients with… read more here.
Keywords: reach; cough; ics laba; patients asthma ... See more keywords
ICS/LABA Combined With Subcutaneous Immunotherapy Modulates the Th17/Treg Imbalance in Asthmatic Children
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.779072
Abstract: Rationale The imbalance of T helper (Th17) cell and regulatory T (Treg) cell are involved in allergic asthma pathogenesis. We hypothesized that ICS/LABA could modulate the Th17/Treg imbalance and that subcutaneous immunotherapy (SCIT) could coordinate… read more here.
Keywords: ics laba; imbalance; th17 treg; asthmatic children ... See more keywords